Quote from flytiger:
Quote from ByLoSellHi:
Okay - this will be the play of the year, possibly.
Short covering is swamping this today.
And we now have competing research notes, with some saying this med won't be approved, and others saying it not only will, but that it represents a 'cancer treatment breakthrough.'
There's literally no middle ground.
Who will be right?
I know you grew up on Grahm/Dodd, but, it just doesn't matter in the short term. The mechanics of this overwhelm every other possible consideration. See how, 1 or 2 oclock play out, and then the last half hour. That'll tell you who is on the hook.
I hate biotechs. lmao.
Seriously.
Quote from tommymoose:
DNDN has over 30% of their shares shorted :eek:
I think its safe to say $10 is easily reachable and who knows what kind of short-squeeze action we'll see.
I've heard estimates in the high teens, so $10 is being conservative. I'm looking forward to trying to game the range which should be pretty big.
Quote from flytiger:
In naked shorts, it could be 100 or 200 percent of their shares shorted. The kick is, to squeeze them which is really next to impossible to do. This is amazing.
The reason why biotechs suck is, they need to go to the well so often, and it's always equity. Wall St. cannot fathom that a drug that stops melanoma may be more important than that new Bentley, so they scam the deals. Now, they've got their balls in a vice. But they won't quit, so pay attentionl.